logo
Top Things Your Patients Need to Know About Asthma

Top Things Your Patients Need to Know About Asthma

Medscape4 hours ago

The roughly 28 million Americans living with asthma are familiar with the challenges of inflammation and narrowing of the airways that affects how the lungs are supplied with air. That's not including the typical symptoms, such as wheezing, shortness of breath, chest tightness, and coughing.
And, while medication and lifestyle modifications usually work to help manage these symptoms, full-blown attacks can occur due to airway tightness, and these attacks can be life-threatening.
' Asthma is most often a chronic condition and needs to be thought of that way,' said Morris Nejat, MD, who specializes in adult and pediatric allergy and immunology and is owner and chief medical officer of NY Allergy and Sinus Centers in New York City. Doctors, he said, should do detailed review of a patient's health history and perform breathing and lung function testing to measure how severe the condition is.
As a physician, you should encourage patients not to ignore asthma symptoms — no matter what they are.
'Keep an eye on your cough, wheezing, shortness of breath, and chest pain,' is what Diane Cymerman, MD, who specializes in allergy, asthma, and immunology at Stony Brook Medicine in Stony Brook, New York, says patients should be told. 'It's also important that you aren't relying solely on albuterol-type inhalers. If you need an albuterol-type inhaler more than 2 times per week, it's time to see a physician to begin asthma controller medications.'
Here are five important things patients should know about asthma:
1. Watch for Early Symptoms
If a patient has never been officially diagnosed with asthma, one sign that they might be developing the condition is long-term or persistent dry coughing, particularly at night or upon waking up. Routinely experiencing shortness of breath or chest tightness may also be an early sign of asthma.
'Cough is the most common symptom of asthma and usually starts long before asthma advances to wheezing,' said Angela Duff Hogan, MD, chair of the asthma committee of the American College of Allergy, Asthma, and Immunology. 'Recognizing this early symptom can help stop a full-blown asthma attack.'
2. Learn the Triggers
While asthma triggers can sometimes depend on one's age, the long list of factors that can prompt asthma include bacterial sinus and respiratory infections — especially common viral infections. High on the list as well: Pollution, smog, strong odors or fumes, and lung irritants, including cigarette smoke or even sitting near a campfire.
'Exercise and taking aspirin or NSAIDs can also play a role in worsening asthma symptoms,' Hogan said. 'Emotional triggers, including stress, can also prompt asthma.'
Other triggers that can exacerbate asthma symptoms include al lergens such as dust mites, roaches, pet dander, pollen, and mold spores.
Allergy testing can identify what exactly a patient is allergic to, although that may require a referral to a specialist. Also, Nejat said, suggesting patients keep a diary of symptoms can be extremely helpful, especially when preparing for an appointment with an asthma specialist.
3. Fluctuating Weather
It's normal to feel a worsening of asthma symptoms during extreme weather changes. In addition, damp weather spreads pollen and mold, which is yet another asthma trigger. Climate change, including longer pollen seasons and wildfires, have also contributed to breathing issues for those with the condition.
' The weather can certainly affect asthma,' Hogan said. 'Very cold air can cause the muscles that line your lung airways to tighten, and extremely hot temperatures can cause dehydration, which worsens asthma by thickening mucus, making it harder to breathe.'
4. Age of Diagnosis
While one can develop asthma at any age, a family history of asthma and the presence of other allergy conditions could play a pivotal role.
In addition, adult-onset asthma (meaning a diagnosis in anyone older than 20 years) is currently being studied due to the increase in adults developing asthma.
The reasons for the connection aren't exactly clear but may relate to having a history of allergies (around 30% of adult asthma is triggered by allergies), acid reflux, or being exposed to certain irritants or air pollution.
5. Always Be Prepared
Treatments for asthma can vary. For patients with well-controlled asthma, treatments can include maintenance inhaler therapy (or a rescue inhaler) for symptoms like coughing or wheezing. Inhaled corticosteroids may also be beneficial.
Patients should always have their medicines handy — and never use expired medication. It's also critical that patients both know how to correctly use an inhaler and have an asthma action plan.
A patient should never wait until their wheezing to get some relief. 'Let your inhaler be your bestie,' Hogan tells patients. 'Make sure you have it available and use it when you should.'
If, however, a patient feels like their usual medications aren't effective, they shouldn't hesitate to seek out another option.
'You'll want to make sure your asthma specialist assesses the cause and offers you the best management of your symptoms,' Cymerman said.
One final note for patients: 'Just because you feel 'well' doesn't mean that your asthma is gone or that you should stop your controller medicine,' Hogan said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Q&A: New Myeloma Bispecific Rivals CAR T in Early Data
Q&A: New Myeloma Bispecific Rivals CAR T in Early Data

Medscape

timean hour ago

  • Medscape

Q&A: New Myeloma Bispecific Rivals CAR T in Early Data

CHICAGO — Two early-phase clinical trials released data at the American Society of Clinical Oncology (ASCO) 2025 annual meeting that suggest their premise — an elranatamab-based triplet regimen and a new trispecific regimen — shows good potential in multiple myeloma (MM). 'It was interesting to see where these new lines of thought will take us in treating myeloma. Elranatamab is already approved in the third-line setting in the US, and using it in the frontline setting in MagnetisMM-6 shows promise,' said oral abstract session discussant Amrita Krishnan, MD, of the City of Hope Comprehensive Cancer Center in Duarte, California. 'And the first-in-human data from JNJ-5322 shows the drug has incredible activity.' 'In both these trials, we need to see if their responses hold,' Krishnan added. Early MagnetisMM-6 Readout The key takeaway from MagnetisMM-6 Part 1, dose level G, is that initial data show that the triplet combination of elranatamab with daratumumab and lenalidomide is effective and manageable in patients with newly diagnosed MM who are not eligible for transplant. That's according to study author Hang Quach, MD, of St Vincent's Hospital Melbourne, University of Melbourne, in Melbourne, Australia. Elranatamab is a B-cell maturation antigen (BCMA)-CD3 bispecific antibody approved as a late-line monotherapy in relapsed or refractory multiple myeloma. Quach and co-authors hypothesized that adding daratumumab and lenalidomide may enhance immune cell-mediated myeloma cell death. MagnetisMM-6 enrolled 37 patients with transplant-ineligible newly diagnosed MM. Of these, 34 received the triplet regimen. At data cutoff, the median follow-up was 7.9 months, and 32 patients were still on treatment. 'The combination showed early and promising efficacy, and we expect responses to deepen with longer follow-up,' Quach said. Quach reported that the safety profile was predictable and consistent with the components' known toxicities. Treatment-related adverse events were seen in more than 50% of patients. The most common were hematologic AEs, infections, and cytokine release syndrome (CRS). All CRS events were grade 2 or less, and one grade 2 immune effector cell-associated neurotoxicity syndrome event occurred. The phase 3 MagnetisMM-6 Part 2 trial, which will open soon, will evaluate the same elranatamab triplet combination against daratumumab plus lenalidomide plus dexamethasone in transplant-ineligible and transplant-deferred patients with newly diagnosed MM. The study design is patient-centric regarding dosing frequency and de-escalation, Quach said: 'There will be a response-adapted scheduling modification upon achievement of complete response after 12 months at least.' JNJ-5322: First-in-Human Trial The first-in-human trial of JNJ-5322, a BCMA- and GPRC5D-targeted T-cell redirecting trispecific antibody, enrolled 147 patients. 'We treated these patients with different doses and at different dosing schedules and defined the recommended phase 2 dose (RP2D) as 100 mg administered every 4 weeks subcutaneously with only one step-up dose,' said Niels W.C.J. van de Donk, MD, PhD, of Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. 'At the RP2D, we see a manageable safety profile with improved or similar GPRC5D-related adverse events.' As expected, infections were common. The grade 3 or 4 infection rate was 28.6% with prophylactic infection management. GPRC5D-related oral side effects were also observed in the study. Taste-related changes were observed in 60% of patients, while other non-taste-related oral AEs were less frequent and included dry mouth, dysphagia, stomatitis, and decreased appetite. 'The frequency and severity of these oral adverse events is lower than what is typically seen,' van de Donk said. 'And this milder oral treatment emergent AE profile is also reflected in that only 6% of the patients had a transient weight loss of grade 1 or grade 2.' Among patients naive to BCMA- and GPRC5D-targeted therapies and treated at the RP2D, the investigators observed a 100% response rate, a complete response (CR) rate of 70%, and at least a very good partial response in 96%. 'And this deep response translates into a promising progression-free survival of 95% at 1 year,' van de Donk said. 'Overall, JNJ-5532 demonstrated a manageable safety profile and an overall response rate comparable to CAR [chimeric antigen receptor] T with convenient off-the-shelf every 4 weeks dosing with one step-up dose to facilitate outpatient dosing.' Following this presentation, Krishnan sat down with Medscape Medical News . The following interview has been edited for clarity. What is the premise of the MagnetisMM-6 trial? The rationale for using elranatamab in the upfront, newly diagnosed setting is that, in a newly diagnosed myeloma, you probably have healthier T cells than a patient with heavily pretreated disease. The hope is that this drug may work even better in this setting. What stood out to you about MagnetisMM-6's trial design? Participants had a median age of 75 years, which is old for a trial, and 24% of them were frail, which is also quite notable. Patients had a very deep response, which is encouraging in this newly diagnosed setting. The approved dose of elranatamab is weekly, but the investigators gave it only once every 4 weeks, which may be in part why they had a much more favorable safety profile in terms of risk for infection. What will you be watching for from MagnetisMM-6? The data looked promising, but the follow-up is very short. On this trial it's about 7.9 months, so we really need to see if the responses hold and how deep the responses are. What is the premise of the JNJ-5532 trial? The drug targets both GPRC5D and BCMA, with the idea being that, if you hit both targets at once, maybe your response rates are higher than hitting just one target, and that appears to be the case. The reported response rates of 100% are certainly dramatic, but the follow-up right now is very short. What stood out to you about JNJ-5532? With most of the bispecifics, the response rates are about 60%-70%. Now we're looking at a response rate that's close to CAR T-cell therapy for the first time, and it's frankly incredible. But the attractive thing with CAR T has always been 'one and done' vs staying on treatment for a fixed duration or even indefinitely. If you're still having to give patients a drug for, say, 5 years, that's probably not as attractive. Is JNJ-5532 likely to be better tolerated than CAR T? We haven't seen any neurologic toxicity yet, so that's encouraging. And the logistics, of course, are much easier. With JNJ-5532, you get one step-up dose, and it can be given outpatient. So, the comparison with CAR T is not just about side effects: The whole burden of care is very different, and the ability to get it in the community versus entirely inpatient is another big issue in terms of access. MagnetisMM-6 was funded by Pfizer. Quach disclosed relationships with Antengene (Inst), Amgen, Bristol Myers Squibb/Celgene, Celgene, GlaxoSmithKline (Inst), Janssen-Cilag, Karyopharm Therapeutics (Inst), Pfizer, roche, and Sanofi (Inst). JNJ-5532 was funded by Johnson & Johnson. van de Donk reported ties with Adaptive Biotechnologies (Inst), Amgen (Inst), Bayer (Inst), Bristol Myers Squibb Foundation (Inst), Celgene (Inst), Cellectis (Inst), Janssen (Inst), Merck (Inst), Novartis (Inst), Roche (Inst), Servier (Inst), and Takeda (Inst).

Senators Ricketts, Fetterman unite against China's quiet invasion of US farmland
Senators Ricketts, Fetterman unite against China's quiet invasion of US farmland

Fox News

timean hour ago

  • Fox News

Senators Ricketts, Fetterman unite against China's quiet invasion of US farmland

EXCLUSIVE: Republican Sen. Pete Ricketts is leading the charge with Democrat Sen. John Fetterman to codify oversight on foreign countries buying American farmland. The bipartisan Agricultural Foreign Investment Disclosure (AFIDA) Improvements Act seeks to implement recommendations published by the Government Accountability Office (GAO) in January 2024, which found the AFIDA was ill-equipped to combat foreign ownership of American agricultural land. "Communist China is our greatest geopolitical threat," Ricketts told Fox News Digital in an exclusive interview, adding, "This is a way for us to improve the disclosure that's going on with regard to the purchase of this agricultural land, so we can take other action if necessary to make sure we're not giving Communist China the opportunity to buy agricultural land." The bill's proposal comes as two Chinese nationals – a University of Michigan post-doctoral research fellow, Yunqing Jian, and Huazhong University of Science and Technology student Chengxuan Han – were held in federal custody after they were accused of smuggling biological materials into the United States. The suspects have been charged with "smuggling a fungus that has been described as a "potential agroterrorism weapon" into the heartland of America, where they apparently intended to use a University of Michigan laboratory to further their scheme," interm U.S. Attorney for the Eastern District of Michigan Jerome Gorgon said in a statement. The fungus causes a "head blight," described as a disease of wheat, maize, rice and barley, and is responsible for billions of dollars of economic losses throughout the world each year, according to the Department of Justice. If ingested by humans, the substance can cause vomiting, liver damage and "reproductive defects in humans and livestock." Department of Homeland Security Assistant Secretary Tricia McLaughlin told Fox News Digital that the Trump administration is focused on "keeping our homeland secure" through enhanced border screenings. "Protecting America's food supply and national security remains a top priority. Last week's smuggling attempt by Chinese nationals of Fusarium graminearum, a dangerous crop-destroying fungus, posing a significant bioterrorism threat, only highlights this imperative to combat this threat," McLaughlin said. "That could potentially be very damaging to agriculture," Ricketts told Fox News Digital. "We also know that Chinese nationals have been trying to steal our biotechnology with regard to agriculture. They've also been crashing gates of bases. Supposed Chinese tourists have been flying drones around bases. Of course, the Chinese flew a surveillance balloon over our country when the Biden administration just let that happen." Ricketts said China has been aggressively buying American agriculture, "which is why we need to have a heightened sense of vigilance around protecting our homeland." Foreign investors own over 40 million acres of agricultural land in the United States, and between 2010 and 2021, Chinese ownership of American agricultural land increased from 13,720 acres to 383,935 acres, according to the U.S. Department of Agriculture (USDA). "It's not just about the number of acres that they own, but the fact that they own it around Grand Forks Air Force Base in North Dakota or Fort Liberty in North Carolina. They're buying it around sensitive military installations," Ricketts said. The bill, also co-sponsored by Sens. Tommy Tuberville of Alabama, John Cornyn of Texas, Roger Wicker of Mississippi and Rep. Don Bacon of Nebraska, requires AFIDA reporting for foreign persons holding more than 1% interest in American agricultural land. The AFIDA Improvements Act aims to increase information-sharing between the Committee on Foreign Investment in the United States and the USDA. It also requires updates to the AFIDA's handbook and establishes a deadline for USDA to set up an online AFIDA system. Based on the GAO's recommendations, the bill seeks to update the Agricultural Foreign Investment Disclosure Act of 1978 to better equip the USDA to combat foreign adversaries' ownership of American agricultural land. "We are at the most dangerous point in our history right now since World War II," Ricketts said. "We have to be investing in our military. We have to be supporting our friends around the world that are pushing back on these dictators. Communist China is one of them." Additionally, the bill comes as conflict in the Middle East reaches a boiling point between Iran and Israel, reigniting concerns about national security. Israel successfully coordinated attacks against Iran from inside the country, and Ricketts pointed to Ukraine's success in targeting a Russian air base. "What Ukraine was able to do against Russia with their operation that destroyed some of their strategic bombers, and they placed trucks with drones close to an air base and had those drones attack their squadrons. We could be vulnerable to the same thing if China did that here. They've owned farmland close enough to our air bases to be able to launch a drone strike. That should be very concerning to us," Ricketts said. Ricketts added that American farmland should not be a "tool that our adversaries, like Communist China, can use to attack us from inside our own country." There has been little movement on the bill since it was just recently introduced. That is largely because Senate Republicans are narrowly focused on advancing Trump's "big, beautiful bill" ahead of a self-imposed July 4 deadline.

Republicans demand answers on blue state health program accused of leaking patient data to Big Tech
Republicans demand answers on blue state health program accused of leaking patient data to Big Tech

Fox News

timean hour ago

  • Fox News

Republicans demand answers on blue state health program accused of leaking patient data to Big Tech

FIRST ON FOX: House Republicans are putting California's state-run public health insurance exchange on notice with a letter demanding answers about its leaking of private patient data to third-party entries as part of a marketing effort. Spearheaded by several Republicans on the House Energy and Commerce Committee, the letter to Covered California, which facilitates public health insurance for millions of Californians, seeks answers to numerous questions about its alleged leak of private patient data to third-party entities, such as LinkedIn and Google. "Ensuring the confidentiality of health information is a foundational obligation for entities operating within the health insurance ecosystem," the letter, signed by five Republican leaders in the House, states. It points out how federal privacy protections, in particular those stemming from the Health Insurance Portability and Accountability Act (HIPAA), establish certain "expectations" for how organizations like Covered California must handle patient information. Additionally, in California, the law requires consumers provide permission to certain organizations before their medical information can be disclosed to third-parties. "Recent reports and public filings raised questions about whether those expectations were met in this case, and whether existing oversight mechanisms are sufficient to detect and prevent improper disclosures," the Republicans' letter asserted. Following public criticism in late April, alleging that Covered California was passing sensitive patient data to LinkedIn via a network of "trackers" on its website, the state-run health insurance exchange removed them. The criticism stemmed from a forensic analysis by two investigative nonprofits, which found Covered California's website was sharing patients' answers to questions, such as whether one is pregnant, or how many prescription drugs they use, or how often they see doctors, were being passed to LinkedIn without the patients' knowledge or consent. Other questions included demographic information and other sensitive personal data, and Covered California subsequently admitted to sharing patients' Social Security numbers. In total, Covered California had more than 60 active "trackers" on various data points, according to Cal Matters, one of the investigative nonprofits that uncovered the leaked data. Cal Matters, in their investigation, pointed out how the average number of trackers across more than 200 government websites it investigated was only three. Following the Cal Matters report that led to public criticism, Coverd California subsequently explained that the "trackers" it had functioning on its website were part of an advertising campaign initiated in February 2024, and upon discovery of the data sharing, it removed them in April the following year. "Covered California leverages LinkedIn's advertising platform tools, including LinkedIn Insight tags, which are pieces of code added to a website to help track how visitors interact with the site. This tool allows us to better understand consumer behavior and deliver tailored messages to help consumers make informed decisions about their health care options," Covered California said in a public statement put out following the Cal Matters report. "While the review is still ongoing, Covered California has identified that some sensitive data was inadvertently collected by the tags, including first names, the last four digits of Social Security numbers, and other sensitive health information like pregnancy status." The state health insurance exchange added that it was reviewing its entire website to ensure no more analytical tools were improperly collecting or sharing sensitive patient data. Meanwhile, days after Cal Matters brought the data-sharing concerns involving Covered California to light, a class-action lawsuit was filed against LinkedIn and Google, accusing the companies of operating software enabling them "to intercept sensitive and confidential communications of Covered California customers." The letter from House Republicans marks the latest attempt to increase pressure on the California-run public health insurance exchange. Republicans are demanding answers to questions pertaining to its data sharing, including during the period of time it was allegedly sharing info with LinkedIn, as well as questions about what Covered California is currently doing to protect its patients' data. "Americans deserve to know that their sensitive health data is secure and being handled prudently," Chairman Guthrie said following transmission of the letter to Covered California. "We are hopeful that California will be transparent and forthcoming about this apparent data security failure as we launch our investigation." "The unauthorized sharing of private health data with third-party advertisers— including pregnancy status, prescription drug use, and Social Security information— is deeply troubling," added California Rep. Jay Obernolte, a fellow Republican on the House Energy and Commerce Committee who helped spearhead the letter to Covered California alongside Guthrie. "We're seeking answers because the people of California deserve accountability and transparency when their privacy is compromised." When reached for comment, Covered California acknowledged receipt of the letter from Guthrie, Obernolte, and others on the House Energy and Commerce Committee, adding that they were currently reviewing its requests and plan to respond by the provided July 1 deadline. Google and LinkedIn declined to provide comment for this article.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store